Treatment of cytomegalovirus infection

E. C. Reed, J. D. Meyers

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Passive immunotherapy with high doses of pooled unscreened immunoglobulins or immunoglobulin specifically prepared from donors with high levels of antibody to CMV has few adverse side-effects and is succesful in producing good increments in CMV antibody levels. The conflicting results of treatment trials and the lack of a demonstrated antiviral effect in vivo do not encourage the use of immunoglobulin alone for the treatment of CMV disease. The prophylactic effectiveness of immunoglobulin for CMV disease in seronegative marrow transplant patients is also questionable, although there is some indication that prophylaxis in patients with less severe immune defects (for example, renal transplant patients) may be useful.

Original languageEnglish (US)
Pages (from-to)831-852
Number of pages22
JournalClinics in Laboratory Medicine
Volume7
Issue number4
StatePublished - Dec 1 1987

Fingerprint

Cytomegalovirus Infections
Immunoglobulins
Transplants
Passive Immunization
Antibodies
Therapeutics
Antiviral Agents
Bone Marrow
Tissue Donors
Kidney
Defects

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Treatment of cytomegalovirus infection. / Reed, E. C.; Meyers, J. D.

In: Clinics in Laboratory Medicine, Vol. 7, No. 4, 01.12.1987, p. 831-852.

Research output: Contribution to journalReview article

Reed, EC & Meyers, JD 1987, 'Treatment of cytomegalovirus infection', Clinics in Laboratory Medicine, vol. 7, no. 4, pp. 831-852.
Reed, E. C. ; Meyers, J. D. / Treatment of cytomegalovirus infection. In: Clinics in Laboratory Medicine. 1987 ; Vol. 7, No. 4. pp. 831-852.
@article{c29cbc616d904109aaf4dd46e64bce53,
title = "Treatment of cytomegalovirus infection",
abstract = "Passive immunotherapy with high doses of pooled unscreened immunoglobulins or immunoglobulin specifically prepared from donors with high levels of antibody to CMV has few adverse side-effects and is succesful in producing good increments in CMV antibody levels. The conflicting results of treatment trials and the lack of a demonstrated antiviral effect in vivo do not encourage the use of immunoglobulin alone for the treatment of CMV disease. The prophylactic effectiveness of immunoglobulin for CMV disease in seronegative marrow transplant patients is also questionable, although there is some indication that prophylaxis in patients with less severe immune defects (for example, renal transplant patients) may be useful.",
author = "Reed, {E. C.} and Meyers, {J. D.}",
year = "1987",
month = "12",
day = "1",
language = "English (US)",
volume = "7",
pages = "831--852",
journal = "Clinics in Laboratory Medicine",
issn = "0272-2712",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Treatment of cytomegalovirus infection

AU - Reed, E. C.

AU - Meyers, J. D.

PY - 1987/12/1

Y1 - 1987/12/1

N2 - Passive immunotherapy with high doses of pooled unscreened immunoglobulins or immunoglobulin specifically prepared from donors with high levels of antibody to CMV has few adverse side-effects and is succesful in producing good increments in CMV antibody levels. The conflicting results of treatment trials and the lack of a demonstrated antiviral effect in vivo do not encourage the use of immunoglobulin alone for the treatment of CMV disease. The prophylactic effectiveness of immunoglobulin for CMV disease in seronegative marrow transplant patients is also questionable, although there is some indication that prophylaxis in patients with less severe immune defects (for example, renal transplant patients) may be useful.

AB - Passive immunotherapy with high doses of pooled unscreened immunoglobulins or immunoglobulin specifically prepared from donors with high levels of antibody to CMV has few adverse side-effects and is succesful in producing good increments in CMV antibody levels. The conflicting results of treatment trials and the lack of a demonstrated antiviral effect in vivo do not encourage the use of immunoglobulin alone for the treatment of CMV disease. The prophylactic effectiveness of immunoglobulin for CMV disease in seronegative marrow transplant patients is also questionable, although there is some indication that prophylaxis in patients with less severe immune defects (for example, renal transplant patients) may be useful.

UR - http://www.scopus.com/inward/record.url?scp=0023569318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023569318&partnerID=8YFLogxK

M3 - Review article

C2 - 2446819

AN - SCOPUS:0023569318

VL - 7

SP - 831

EP - 852

JO - Clinics in Laboratory Medicine

JF - Clinics in Laboratory Medicine

SN - 0272-2712

IS - 4

ER -